1McCabe DJ, Brown MM. Prevention of ischaemic stroke - antiplatclcts. Br Med Bull, 2000, 56(2): 510-525.
2The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet, 1991,338(8779): 1345-1349.
3UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry, 1991,54(12): 1044-1054.
4The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med, 1991,325(18):1261-1266.
5ESPS Group. European stroke prevention study. Stroke, 1990, 21(8): 1122-1130.
6Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci, 1996, 143(1-2): 1-13.
7Antiplatelet Trialist′ Collaboration. Secondary prevention of vascular disease by prolonged antiphtelet treatment. BMJ, 1988, 296(6618):320-331.
8Antiplatelet Trialist' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 1994, 308(6921 ): 81-106.
9Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry, 1996, 60(2): 197-199.
10Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry, 1999, 66(2): 255.
